SEARL Pharmaceuticals: Major
Health Technology
Mkt Cap
56.2B
P/E (TTM)
46.89
EPS
-2.36
ROE
6.59%
Div Yield
—
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 28.60B | 29.40B | 25.80B | 29.91B | 26.22B | |
| Cost of Goods Sold | -14.69B | -15.99B | -14.58B | -17.14B | -14.31B | |
| Gross Profit | 13.91B | 13.41B | 11.22B | 12.77B | 11.91B | |
| SG&A Expenses | -10.19B | -8.64B | -7.43B | -6.84B | -6.17B | |
| Research & Development | -47.13M | -40.62M | -59.16M | -68.73M | -70.39M | |
| Depreciation | -733.29M | -807.86M | -652.23M | -553.84M | -419.16M | |
| Other Operating Expense | -64.75M | -137.35M | -90.89M | -31.53M | -40.01M | |
| Total Operating Expense | -24.94B | -24.77B | -22.10B | -24.01B | -20.51B | |
| Operating Income (EBIT) | 3.66B | 4.63B | 3.69B | 5.90B | 5.71B | |
| Interest Income | 17.00M | 23.64M | 18.91M | 12.28M | 20.57M | |
| Interest Expense | -2.04B | -3.62B | -3.23B | -2.04B | -1.39B | |
| Equity in Earnings | 0 | 0 | 0 | 0 | 0 | |
| Other Non-Operating Income | -111.69M | -106.40M | -320.78M | -259.71M | 622.14M | |
| Total Non-Operating Income | -2.13B | -3.41B | -3.50B | -2.24B | -670.53M | |
| Pre-Tax Income | 1.53B | 1.21B | 190.72M | 3.66B | 5.04B | |
| Income Tax | -723.86M | -229.58M | -226.34M | -1.25B | -1.29B | |
| Minority Interest | -18.05M | 7.92M | -64.49M | -64.22M | -67.93M | |
| Net Income | -1.39B | -2.40B | 348.57M | 2.35B | 3.68B | |
| EBITDA | 4.41B | 5.46B | 4.37B | 6.49B | 6.18B | |
| EPS (Basic) | -2.36 | -4.35 | 0.72 | 5.03 | 8.11 | |
| EPS (Diluted) | -2.36 | -4.35 | 0.72 | 5.03 | 8.11 | |
| Gross Margin | 48.64% | 45.60% | 43.50% | 42.69% | 45.44% | |
| Operating Margin | 12.79% | 15.74% | 14.32% | 19.72% | 21.76% | |
| EBITDA Margin | 15.42% | 18.58% | 16.95% | 21.71% | 23.55% | |
| Pre-Tax Margin | 5.35% | 4.13% | 0.74% | 12.24% | 19.20% | |
| Net Margin | 2.76% | 3.37% | -0.39% | 7.86% | 14.03% |